相似文献
1
Treatment of native valve endocarditis with rezafungin: a case report.
JAC Antimicrob Resist. 2024 Mar 12;6(2):dlae042. doi: 10.1093/jacamr/dlae042. eCollection 2024 Apr.
2
Evaluation of the Post-Antifungal Effect of Rezafungin and Micafungin against Candida albicans, Candida parapsilosis and Candida glabrata.
Mycoses. 2022 Nov;65(11):1040-1044. doi: 10.1111/myc.13490. Epub 2022 Jul 18.
3
Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020).
J Clin Microbiol. 2022 Apr 20;60(4):e0244921. doi: 10.1128/jcm.02449-21. Epub 2022 Mar 7.
4
Expanded Access Use of Rezafungin for Salvage Therapy of Invasive Infection: A Case Report.
Open Forum Infect Dis. 2021 Aug 28;8(11):ofab431. doi: 10.1093/ofid/ofab431. eCollection 2021 Nov.
5
In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae.
J Antimicrob Chemother. 2019 Dec 1;74(12):3505-3510. doi: 10.1093/jac/dkz390.
6
Candida glabrata meningitis and endocarditis: a late severe complication of candidemia.
Int J Infect Dis. 2014 Dec;29:174-5. doi: 10.1016/j.ijid.2014.04.032. Epub 2014 Oct 27.
7
EUCAST Reference Testing of Rezafungin Susceptibility and Impact of Choice of Plastic Plates.
Antimicrob Agents Chemother. 2019 Aug 23;63(9). doi: 10.1128/AAC.00659-19. Print 2019 Sep.
8
Candida and cardiovascular implantable electronic devices: a case of lead and native aortic valve endocarditis and literature review.
Mycoses. 2015 Nov;58(11):637-41. doi: 10.1111/myc.12391. Epub 2015 Sep 25.
9
Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018).
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.00099-20.
10
A rare case of fungal endocarditis caused by Candida glabrata after completion of antibiotic therapy for Streptococcus endocarditis.
J Med Ultrason (2001). 2015 Apr;42(2):243-6. doi: 10.1007/s10396-014-0580-6. Epub 2014 Oct 15.
引用本文的文献
1
A case of recurrent fungemia and successful treatment with rezafungin.
IDCases. 2025 Apr 20;40:e02233. doi: 10.1016/j.idcr.2025.e02233. eCollection 2025.
2
Rezafungin for suppressive therapy of in a patient with a left ventricular assist device (LVAD).
IDCases. 2025 Apr 18;40:e02232. doi: 10.1016/j.idcr.2025.e02232. eCollection 2025.
3
Long-term Safety and Effectiveness of Rezafungin Treatment in Candidemia and Invasive Candidiasis: Results From an Early Access Program in Italy and Germany.
Open Forum Infect Dis. 2025 Mar 19;12(3):ofaf034. doi: 10.1093/ofid/ofaf034. eCollection 2025 Mar.
4
It's Here, It's There, There's Fungi Everywhere: A Case Series Utilizing Rezafungin for Invasive Candidiasis.
Infect Dis Ther. 2025 Apr;14(4):889-895. doi: 10.1007/s40121-025-01120-7. Epub 2025 Mar 11.
5
New Perspectives on Antimicrobial Agents: Rezafungin.
Antimicrob Agents Chemother. 2025 Jan 31;69(1):e0064623. doi: 10.1128/aac.00646-23. Epub 2024 Dec 12.
6
Safety of rezafungin as a long-term treatment option in two patients with complicated fungal infections: two cases from Lecco Hospital (Italy).
Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0075024. doi: 10.1128/aac.00750-24. Epub 2024 Jul 12.
本文引用的文献
1
Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials.
Lancet Infect Dis. 2024 Mar;24(3):319-328. doi: 10.1016/S1473-3099(23)00551-0. Epub 2023 Nov 23.
2
Candida glabrata: A powerhouse of resistance.
PLoS Pathog. 2023 Oct 5;19(10):e1011651. doi: 10.1371/journal.ppat.1011651. eCollection 2023 Oct.
3
2023 ESC Guidelines for the management of endocarditis.
Eur Heart J. 2023 Oct 14;44(39):3948-4042. doi: 10.1093/eurheartj/ehad193.
4
European candidaemia is characterised by notable differential epidemiology and susceptibility pattern: Results from the ECMM Candida III study.
J Infect. 2023 Nov;87(5):428-437. doi: 10.1016/j.jinf.2023.08.001. Epub 2023 Aug 6.
5
Fungal Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management.
Clin Microbiol Rev. 2023 Sep 21;36(3):e0001923. doi: 10.1128/cmr.00019-23. Epub 2023 Jul 13.
6
Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases.
Open Forum Infect Dis. 2022 Mar 4;9(6):ofac112. doi: 10.1093/ofid/ofac112. eCollection 2022 Jun.
7
Rezafungin-Mechanisms of Action, Susceptibility and Resistance: Similarities and Differences with the Other Echinocandins.
J Fungi (Basel). 2020 Nov 1;6(4):262. doi: 10.3390/jof6040262.
8
We can do better: a fresh look at echinocandin dosing.
J Antimicrob Chemother. 2018 Jan 1;73(suppl_1):i44-i50. doi: 10.1093/jac/dkx448.
9
Candida endocarditis: systematic literature review from 1997 to 2014 and analysis of 29 cases from the Italian Study of Endocarditis.
Expert Rev Anti Infect Ther. 2017 Sep;15(9):807-818. doi: 10.1080/14787210.2017.1372749. Epub 2017 Sep 14.
10
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.
Clin Infect Dis. 2016 Feb 15;62(4):e1-50. doi: 10.1093/cid/civ933. Epub 2015 Dec 16.
Zotero 插件